Hypera S.A.

Hypera reported 2Q26 net revenue of BRL 2.34 billion, up 8.5% year over year, with sell-out growth of 7.6%. Gross margin was 61.8%, up 1.7 percentage points versus 2Q25 and 1.8 percentage points versus 1Q26, while EBITDA from continuing operations was BRL 755 million with a 32.3% margin. Net income grew 15%, helped by lower financial expenses after the BRL 1.5 billion capital increase in 1Q26. Operating cash flow was BRL 819 million, or 108.5% of EBITDA, free cash flow was BRL 638 million, and net debt fell to BRL 5.9 billion, equal to 2.1x last-12-month EBITDA. For 2026, management said CapEx will remain high because of strategic projects, especially the institutional market plant, and only start to decline after 2027, maybe 2028.

Breno Oliveira framed the quarter as proof Hypera can deliver short-term financial performance while building long-term growth options through innovation. He highlighted progress in skincare, CNS, and gut health, plus new launches that added 2.2 percentage points to sell-out growth. He was upbeat about the upcoming Semavy launch and the new non-hormonal menopausal treatment, saying both should expand Hypera’s presence in attractive, innovative markets.

Ramon Sanches emphasized the financial quality of the quarter: revenue up 8.5% to BRL 2.34 billion, gross margin at 61.8%, EBITDA of BRL 755 million, and operating cash flow of BRL 819 million. He attributed margin expansion mainly to price increases outpacing input costs and said the company is converting operating income into cash efficiently, with first-half operating cash flow matching EBITDA. He also noted BRL 1.3 billion in interest and amortization payments, including early redemption of the 15th debenture issue, net debt down nearly BRL 400 million to BRL 5.9 billion, and a lower debt cost below CDI.

Analysts focused on working capital, the size and timing of new-category contributions, GLP-1 competition, CapEx, and the launch mechanics for Semavy. Management said inventory reductions are a structural, ongoing gain from the internal working-capital review, not a one-off, though first-quarter metrics can still look seasonally higher because sales are lower. On Semavy, Breno said Hypera’s edge is its Mantecorp brand, medical sales force, nationwide distribution, and ability to sell a broader prescription basket alongside GLP-1s, while Ramon said launch sales should start in September after CMED pricing and that CapEx remains elevated in 2026 before easing after 2027.